Cipla wins FDA nod for Advair generic
NiveshIQ
NSE: CIPLA · Pharma
Cipla Ltd.
₹1,474.30▲ ₹29.70 (+2.06%)
Price Chart · Daily closes
1Y
6M
3M
1M
1W
1D
⚡ Intelligence Signals
5 active
🟢 Bullish Earnings Catalyst
📊 RS Laggard (5D)
🔄 Sector Sweep
⚡ Signals Aligned
📉 Pullback
NiveshIQ has detected 5 active signals on CIPLA. Sign up free to see what each signal means and how it affects the stock.
Unlock signals — freeExpected Move
1D / 1W / 1M range derived from news, fundamentals & technicals
1 Day
±1.8%
1 Week
±4.2%
1 Month
±9.6%
Confidence Score
Based on historical directional & magnitude accuracy for this stock
74
/ 100
About Cipla Ltd.
Cipla Limited is a leading Indian pharmaceutical company with a diversified portfolio of generic and branded generic medicines, vaccines, and formulations across various therapeutic areas. The company has a strong presence in India, the United States, South Africa, and internationally, with a revenue of ₹27,828 crore. Cipla's key revenue drivers include its generic medicines, biosimilars, and specialty businesses. Recent developments have seen the company's Q1 consolidated net profit drop to ₹8 billion, missing Street estimates, and its share price fall over 3% after Q1 FY27 results. Despite this, the company has a record Q1 revenue driven by India growth, new launches, and global market expansion. Cipla's competitive position is strong, with a diversified portfolio and a presence in multi
Financial Highlights
| Metric | FY24 | FY25 | FY26 |
|---|---|---|---|
| Revenue | ₹25,774 Cr +13.30% | ₹27,548 Cr +6.90% | ₹28,163 Cr +2.20% |
| EBITDA Margin | 24.41% | 25.88% | 24.02% |
| Net Profit | ₹4,153 Cr +46.60% | ₹5,269 Cr +26.90% | ₹3,862 Cr -26.70% |
| EPS | ₹51.05 | ₹65.29 | ₹48.03 |
Annual figures in Indian Rupees (Crores). Source: BSE filings.
Recent News
Nearly four years behind schedule, Cipla has won the USFDA approval for its generic version of Advair. The approval opens the door to a US market estimated at nearly $900 million a
Cipla Receives US FDA Approval for Generic Advair Diskus in All Three Strengths
🔒
+ 3 more stories about Cipla Ltd.
Full news feed with AI impact summaries, synced in real time.
Sign up free — it's instantStrategic Outlook
- Q1FY27 results: revenue ₹7, 119 Cr, PAT ₹786 Cr, EPS ₹9.77, EBITDA margin 19.7%. Growth context: revenue QoQ +8.8%, PAT QoQ +44.8%. Street verdict: miss, revenue surprise -0.2%, PAT surprise -6.7%.
Management's near-term growth strategy is centered on product launches, approvals, and therapy-mix improvement, as well ...
FY26 (last completed FY): revenue ₹28, 163 Cr, PAT ₹3, 862 Cr, EBITDA margin 24.0%, EPS ₹48.03. Year-on-year: revenue Yo...
🔒
+ 3 more outlook points
Growth drivers, key risks, and upcoming catalysts — unlocked free.
Sign up free — it's instantEverything you unlock with a free account
⚡Intelligence Signals — AI-detected patterns across news, earnings & technicals
📈Price Chart — 1D to 1Y daily closes for CIPLA
🎯Expected Move — 1D / 1W / 1M range from news, fundamentals & technicals
🧠Confidence Score — Historical directional & magnitude accuracy for this stock
🎙Analyst Target Price — Consensus target with buy / hold / sell breakdown
📰Full News Feed — All stories synced in real time with AI impact summaries
🔭Strategic Outlook — Growth drivers, risks & upcoming catalysts
📊Watchlist & Portfolio — Track CIPLA alongside your other holdings
Unlock full CIPLA research — free
No credit card · No trial · Always free to start
Frequently Asked Questions
What AI signals does NiveshIQ provide for Cipla Ltd.?
NiveshIQ detects active intelligence signals for Cipla Ltd. (CIPLA) — including earnings catalysts, relative strength patterns, sector sweeps, and pullback setups. It also shows an Expected Move (1D/1W/1M range based on news, fundamentals and technicals) and a Confidence Score based on historical directional and magnitude accuracy. These are exclusive to NiveshIQ.
What are the key financials for Cipla Ltd.?
Cipla Ltd. operates in the Pharma sector with a market capitalisation of ₹10,888,909.9L Cr. Revenue, net profit, EPS and EBITDA margins across the last three annual periods are shown above, sourced from BSE filings.
Does NiveshIQ provide investment advice?
No. NiveshIQ provides educational market intelligence and research context, not investment advice or buy/sell recommendations.